HCM - Hutchison China MediTech Limited
Hutchison China MediTech Limited
Cheung Kong Center
48th Floor 2 Queen's Road
Central
Hong Kong
852 2121 8200
http://www.chi-med.com
Sector: Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 714
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBA | Exec. Chairman | 167.4k | N/A | 1952 |
| Mr. Christian Hogg B.Sc., M.B.A., BSc, MBA | CEO & Exec. Director | 1.33M | N/A | 1966 |
| Mr. Johnny Cheng C.A., BEc, CA | CFO & Exec. Director | 682.01k | N/A | 1967 |
| Dr. Wei-Guo Su B.Sc., Ph.D. | Chief Scientific Officer, Exec. VP & Exec. Director | 1.09M | N/A | 1957 |
| Ms. Edith Shih B.S., M.A., BSE, MA, EdM, Solicitor, FCIS, FCS(PE) | Company Sec. & Non-Exec. Director | 70k | N/A | 1952 |
Description
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, a c-MET inhibitor for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, a inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; and HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma, as well as HMPL-689, a treatment for indolent non-Hodgkin's lymphoma and healthy volunteers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.
Corporate governance
Hutchison China MediTech Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.